Literature DB >> 16434808

Serum lipoprotein(a) level and clinical coronary stenosis progression in patients with myocardial infarction: re-revascularization rate is high in patients with high-Lp(a).

Yukiko Morita1, Hideo Himeno, Hideyuki Yakuwa, Takashi Usui.   

Abstract

BACKGROUND: High serum lipoprotein(a) (Lp(a)) levels are associated with coronary artery disease. METHODS AND
RESULTS: The serum Lp(a) levels of 130 patients with acute myocardial infarction (AMI) who underwent direct percutaneous coronary intervention were investigated. On the basis of Lp(a) level at 1 month after the onset of AMI, the patients were classified into 2 groups (high-Lp(a) (> or =30 mg/dl) and low-Lp(a) (< 30 mg/dl)) for evaluation of the clinical coronary stenosis progression (CCSP) rate. CCSP is defined as either target lesion revascularization (TLR) or new lesion revascularization (NLR). The CCSP rate was significantly higher in the high-Lp(a) group than in the low-Lp(a) group (65.8% vs 29.3%, p<0.01). In patients who had coronary stents in the acute phase (n=79), the CCSP and NLR rates were significantly higher in the high-Lp(a) group than in the low-Lp(a) group (45.0% vs 20.3%, p<0.05; 35.0% vs 6.8%, p<0.01), but there was no significant difference in TLR rate between the 2 groups (10.0% vs 13.6%, p=0.858).
CONCLUSIONS: High serum Lp(a) level is a significant risk factor for CCSP, but does not influence restenosis after stenting.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434808     DOI: 10.1253/circj.70.156

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  7 in total

1.  Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia.

Authors:  E Meriño-Ibarra; J Puzo; E Jarauta; A Cenarro; D Recalde; A L García-Otín; E Ros; E Martorell; X Pintó; M Franco; D Zambón; A Brea; M Pocoví; F Civeira
Journal:  J Inherit Metab Dis       Date:  2007-10-20       Impact factor: 4.982

2.  High Lipoprotein(a) Levels are Associated With Long-Term Adverse Outcomes in Acute Myocardial Infarction Patients in High Killip Classes.

Authors:  Jae Yeong Cho; Myung Ho Jeong; Youngkeun Ahn; Young Joon Hong; Hyung Wook Park; Nam Sik Yoon; Hyun Ju Yoon; Kye Hun Kim; Ju Han Kim; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang
Journal:  Korean Circ J       Date:  2010-10-31       Impact factor: 3.243

3.  Lipoprotein(a), homocysteine, and retinal arteriosclerosis.

Authors:  Amir Ghorbanihaghjo; Alireza Javadzadeh; Hassan Argani; Nariman Nezami; Nadereh Rashtchizadeh; Mandana Rafeey; Mohammad Rohbaninoubar; Babak Rahimi-Ardabili
Journal:  Mol Vis       Date:  2008-09-15       Impact factor: 2.367

Review 4.  Potential of lipoproteins as biomarkers in acute myocardial infarction.

Authors:  Haseeb Ahmad Khan; Aishah Ekhzaimy; Isra Khan; Meena Kishore Sakharkar
Journal:  Anatol J Cardiol       Date:  2017-07       Impact factor: 1.596

Review 5.  Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction.

Authors:  Enas A Enas; Basil Varkey; T S Dharmarajan; Guillaume Pare; Vinay K Bahl
Journal:  Indian Heart J       Date:  2019-03-20

Review 6.  Lipoprotein(a) in cardiovascular diseases.

Authors:  Michele Malaguarnera; Marco Vacante; Cristina Russo; Giulia Malaguarnera; Tijana Antic; Lucia Malaguarnera; Rita Bella; Giovanni Pennisi; Fabio Galvano; Alessandro Frigiola
Journal:  Biomed Res Int       Date:  2012-12-30       Impact factor: 3.411

7.  High Lipoprotein(a) Levels as a Predictor of Major Adverse Cardiovascular Events in Hospitalized-Acute Myocardial Infarction Patients.

Authors:  I Dewa Gde Dwi Sumarjaya; I Ketut Badjra Nadha; Anak Agung Wiradewi Lestari
Journal:  Vasc Health Risk Manag       Date:  2020-04-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.